Is Micron a Good Stock to Buy Now?
Like most of its peers in the semiconductor industry, Micron…
Sell
30
GSK Quote, Financials, Valuation and Earnings
Last price:
$35.92
Seasonality move
:
2.72%
Day range:
$35.28 - $35.89
52-week range:
$31.72 - $45.93
Dividend yield:
4.4%
P/E ratio:
22.34x
P/S ratio:
1.82x
P/B ratio:
4.20x
Volume:
2.9M
Avg. volume:
5.7M
1-year change:
-11.46%
Market cap:
$72.1B
Revenue:
$40.1B
EPS (TTM):
$1.58
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
GSK
GSK PLC
|
$9.6B | $0.98 | 2.49% | 46.01% | $42.62 |
|
AMGN
Amgen
|
$8B | $4.26 | 5.51% | 285.64% | $317.12 |
|
AZN
AstraZeneca PLC
|
$13.7B | $1.11 | 8.46% | 83.1% | $84.79 |
|
GILD
Gilead Sciences
|
$6.8B | $1.75 | -0.01% | 50.66% | $112.50 |
|
HLN
Haleon PLC
|
$3.8B | $0.32 | 0.78% | 8.98% | $10.71 |
|
NVAX
Novavax
|
$204.1M | $0.54 | -62.65% | -82.16% | $16.43 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
GSK
GSK PLC
|
$35.37 | $42.62 | $72.1B | 22.34x | $0.40 | 4.4% | 1.82x |
|
AMGN
Amgen
|
$282.64 | $317.12 | $151.8B | 37.44x | $2.38 | 3.23% | 4.57x |
|
AZN
AstraZeneca PLC
|
$67.05 | $84.79 | $207.9B | 29.73x | $1.05 | 2.31% | 3.87x |
|
GILD
Gilead Sciences
|
$104.88 | $112.50 | $130.6B | 283.46x | $0.79 | 2.96% | 4.59x |
|
HLN
Haleon PLC
|
$10.16 | $10.71 | $45.9B | 25.25x | $0.05 | 1.56% | 3.25x |
|
NVAX
Novavax
|
$6.20 | $16.43 | $997.2M | -- | $0.00 | 0% | 1.42x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
GSK
GSK PLC
|
53.74% | -0.068 | 29.19% | 0.49x |
|
AMGN
Amgen
|
91.09% | 0.284 | 43.85% | 0.84x |
|
AZN
AstraZeneca PLC
|
41.27% | -0.160 | -- | 0.74x |
|
GILD
Gilead Sciences
|
58.02% | 0.600 | 23.22% | 1.33x |
|
HLN
Haleon PLC
|
38.17% | 0.075 | 28.98% | 0.75x |
|
NVAX
Novavax
|
-37.36% | 8.675 | 13.16% | 0.89x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
GSK
GSK PLC
|
$7.1B | $2.8B | 8.51% | 19.22% | 8.71% | $1.5B |
|
AMGN
Amgen
|
$6B | $2.3B | 5.97% | 66.87% | 16.83% | $4.4B |
|
AZN
AstraZeneca PLC
|
$12.2B | $2B | 9.88% | 17.77% | 14.07% | $2B |
|
GILD
Gilead Sciences
|
$6B | $2.4B | 1.09% | 2.5% | 31.92% | $2.8B |
|
HLN
Haleon PLC
|
$2B | $448.1M | 5.64% | 8.91% | 14.46% | $921M |
|
NVAX
Novavax
|
$51.6M | -$131.1M | -- | -- | -74.73% | -$175.4M |
GSK PLC vs. Competitors
-
Which has Higher Returns GSK or AMGN?
Amgen has a net margin of 5.1% compared to GSK PLC's net margin of 6.9%. GSK PLC's return on equity of 19.22% beat Amgen's return on equity of 66.87%.
Company Gross Margin Earnings Per Share Invested Capital GSKGSK PLC68.47% $0.26 $36.4B AMGNAmgen65.75% $1.16 $66B -
What do Analysts Say About GSK or AMGN?
GSK PLC has a consensus price target of $42.62, signalling upside risk potential of 20.51%. On the other hand Amgen has an analysts' consensus of $317.12 which suggests that it could grow by 12.2%. Given that GSK PLC has higher upside potential than Amgen, analysts believe GSK PLC is more attractive than Amgen.
Company Buy Ratings Hold Ratings Sell Ratings GSKGSK PLC2 4 1 AMGNAmgen9 14 2 -
Is GSK or AMGN More Risky?
GSK PLC has a beta of 0.579, which suggesting that the stock is 42.135% less volatile than S&P 500. In comparison Amgen has a beta of 0.583, suggesting its less volatile than the S&P 500 by 41.682%.
-
Which is a Better Dividend Stock GSK or AMGN?
GSK PLC has a quarterly dividend of $0.40 per share corresponding to a yield of 4.4%. Amgen offers a yield of 3.23% to investors and pays a quarterly dividend of $2.38 per share. GSK PLC pays 94.91% of its earnings as a dividend. Amgen pays out 118.14% of its earnings as a dividend. GSK PLC's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Amgen's is not.
-
Which has Better Financial Ratios GSK or AMGN?
GSK PLC quarterly revenues are $10.4B, which are larger than Amgen quarterly revenues of $9.1B. GSK PLC's net income of $530.1M is lower than Amgen's net income of $627M. Notably, GSK PLC's price-to-earnings ratio is 22.34x while Amgen's PE ratio is 37.44x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for GSK PLC is 1.82x versus 4.57x for Amgen. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GSKGSK PLC1.82x 22.34x $10.4B $530.1M AMGNAmgen4.57x 37.44x $9.1B $627M
-
Which has Higher Returns GSK or AZN?
AstraZeneca PLC has a net margin of 5.1% compared to GSK PLC's net margin of 10.07%. GSK PLC's return on equity of 19.22% beat AstraZeneca PLC's return on equity of 17.77%.
Company Gross Margin Earnings Per Share Invested Capital GSKGSK PLC68.47% $0.26 $36.4B AZNAstraZeneca PLC81.7% $0.48 $69.5B -
What do Analysts Say About GSK or AZN?
GSK PLC has a consensus price target of $42.62, signalling upside risk potential of 20.51%. On the other hand AstraZeneca PLC has an analysts' consensus of $84.79 which suggests that it could grow by 26.46%. Given that AstraZeneca PLC has higher upside potential than GSK PLC, analysts believe AstraZeneca PLC is more attractive than GSK PLC.
Company Buy Ratings Hold Ratings Sell Ratings GSKGSK PLC2 4 1 AZNAstraZeneca PLC6 1 0 -
Is GSK or AZN More Risky?
GSK PLC has a beta of 0.579, which suggesting that the stock is 42.135% less volatile than S&P 500. In comparison AstraZeneca PLC has a beta of 0.485, suggesting its less volatile than the S&P 500 by 51.487%.
-
Which is a Better Dividend Stock GSK or AZN?
GSK PLC has a quarterly dividend of $0.40 per share corresponding to a yield of 4.4%. AstraZeneca PLC offers a yield of 2.31% to investors and pays a quarterly dividend of $1.05 per share. GSK PLC pays 94.91% of its earnings as a dividend. AstraZeneca PLC pays out 65.8% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios GSK or AZN?
GSK PLC quarterly revenues are $10.4B, which are smaller than AstraZeneca PLC quarterly revenues of $14.9B. GSK PLC's net income of $530.1M is lower than AstraZeneca PLC's net income of $1.5B. Notably, GSK PLC's price-to-earnings ratio is 22.34x while AstraZeneca PLC's PE ratio is 29.73x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for GSK PLC is 1.82x versus 3.87x for AstraZeneca PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GSKGSK PLC1.82x 22.34x $10.4B $530.1M AZNAstraZeneca PLC3.87x 29.73x $14.9B $1.5B
-
Which has Higher Returns GSK or GILD?
Gilead Sciences has a net margin of 5.1% compared to GSK PLC's net margin of 23.56%. GSK PLC's return on equity of 19.22% beat Gilead Sciences's return on equity of 2.5%.
Company Gross Margin Earnings Per Share Invested Capital GSKGSK PLC68.47% $0.26 $36.4B GILDGilead Sciences79.11% $1.42 $46B -
What do Analysts Say About GSK or GILD?
GSK PLC has a consensus price target of $42.62, signalling upside risk potential of 20.51%. On the other hand Gilead Sciences has an analysts' consensus of $112.50 which suggests that it could grow by 7.27%. Given that GSK PLC has higher upside potential than Gilead Sciences, analysts believe GSK PLC is more attractive than Gilead Sciences.
Company Buy Ratings Hold Ratings Sell Ratings GSKGSK PLC2 4 1 GILDGilead Sciences14 12 0 -
Is GSK or GILD More Risky?
GSK PLC has a beta of 0.579, which suggesting that the stock is 42.135% less volatile than S&P 500. In comparison Gilead Sciences has a beta of 0.322, suggesting its less volatile than the S&P 500 by 67.831%.
-
Which is a Better Dividend Stock GSK or GILD?
GSK PLC has a quarterly dividend of $0.40 per share corresponding to a yield of 4.4%. Gilead Sciences offers a yield of 2.96% to investors and pays a quarterly dividend of $0.79 per share. GSK PLC pays 94.91% of its earnings as a dividend. Gilead Sciences pays out 816.25% of its earnings as a dividend. GSK PLC's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Gilead Sciences's is not.
-
Which has Better Financial Ratios GSK or GILD?
GSK PLC quarterly revenues are $10.4B, which are larger than Gilead Sciences quarterly revenues of $7.6B. GSK PLC's net income of $530.1M is lower than Gilead Sciences's net income of $1.8B. Notably, GSK PLC's price-to-earnings ratio is 22.34x while Gilead Sciences's PE ratio is 283.46x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for GSK PLC is 1.82x versus 4.59x for Gilead Sciences. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GSKGSK PLC1.82x 22.34x $10.4B $530.1M GILDGilead Sciences4.59x 283.46x $7.6B $1.8B
-
Which has Higher Returns GSK or HLN?
Haleon PLC has a net margin of 5.1% compared to GSK PLC's net margin of 8.37%. GSK PLC's return on equity of 19.22% beat Haleon PLC's return on equity of 8.91%.
Company Gross Margin Earnings Per Share Invested Capital GSKGSK PLC68.47% $0.26 $36.4B HLNHaleon PLC55.38% $0.06 $32.9B -
What do Analysts Say About GSK or HLN?
GSK PLC has a consensus price target of $42.62, signalling upside risk potential of 20.51%. On the other hand Haleon PLC has an analysts' consensus of $10.71 which suggests that it could grow by 5.39%. Given that GSK PLC has higher upside potential than Haleon PLC, analysts believe GSK PLC is more attractive than Haleon PLC.
Company Buy Ratings Hold Ratings Sell Ratings GSKGSK PLC2 4 1 HLNHaleon PLC2 2 0 -
Is GSK or HLN More Risky?
GSK PLC has a beta of 0.579, which suggesting that the stock is 42.135% less volatile than S&P 500. In comparison Haleon PLC has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock GSK or HLN?
GSK PLC has a quarterly dividend of $0.40 per share corresponding to a yield of 4.4%. Haleon PLC offers a yield of 1.56% to investors and pays a quarterly dividend of $0.05 per share. GSK PLC pays 94.91% of its earnings as a dividend. Haleon PLC pays out 39.53% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios GSK or HLN?
GSK PLC quarterly revenues are $10.4B, which are larger than Haleon PLC quarterly revenues of $3.5B. GSK PLC's net income of $530.1M is higher than Haleon PLC's net income of $295.8M. Notably, GSK PLC's price-to-earnings ratio is 22.34x while Haleon PLC's PE ratio is 25.25x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for GSK PLC is 1.82x versus 3.25x for Haleon PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GSKGSK PLC1.82x 22.34x $10.4B $530.1M HLNHaleon PLC3.25x 25.25x $3.5B $295.8M
-
Which has Higher Returns GSK or NVAX?
Novavax has a net margin of 5.1% compared to GSK PLC's net margin of -91.76%. GSK PLC's return on equity of 19.22% beat Novavax's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital GSKGSK PLC68.47% $0.26 $36.4B NVAXNovavax58.48% -$0.51 -$454.2M -
What do Analysts Say About GSK or NVAX?
GSK PLC has a consensus price target of $42.62, signalling upside risk potential of 20.51%. On the other hand Novavax has an analysts' consensus of $16.43 which suggests that it could grow by 164.98%. Given that Novavax has higher upside potential than GSK PLC, analysts believe Novavax is more attractive than GSK PLC.
Company Buy Ratings Hold Ratings Sell Ratings GSKGSK PLC2 4 1 NVAXNovavax3 2 0 -
Is GSK or NVAX More Risky?
GSK PLC has a beta of 0.579, which suggesting that the stock is 42.135% less volatile than S&P 500. In comparison Novavax has a beta of 3.148, suggesting its more volatile than the S&P 500 by 214.784%.
-
Which is a Better Dividend Stock GSK or NVAX?
GSK PLC has a quarterly dividend of $0.40 per share corresponding to a yield of 4.4%. Novavax offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. GSK PLC pays 94.91% of its earnings as a dividend. Novavax pays out -- of its earnings as a dividend. GSK PLC's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios GSK or NVAX?
GSK PLC quarterly revenues are $10.4B, which are larger than Novavax quarterly revenues of $88.3M. GSK PLC's net income of $530.1M is higher than Novavax's net income of -$81M. Notably, GSK PLC's price-to-earnings ratio is 22.34x while Novavax's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for GSK PLC is 1.82x versus 1.42x for Novavax. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GSKGSK PLC1.82x 22.34x $10.4B $530.1M NVAXNovavax1.42x -- $88.3M -$81M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Uber Finally on the Path to Consistent Profitability?
After posting massive losses quarter after quarter for years, Uber…
How High Will MSTY Go By 2030?
YieldMax’s MSTR Option Income Strategy ETF (MSTY) is a high-yield…
Stock Ideas
Sell
48
Is AAPL Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 32x
Sell
46
Is MSFT Stock a Buy?
Market Cap: $2.8T
P/E Ratio: 31x
Sell
42
Is NVDA Stock a Buy?
Market Cap: $2.5T
P/E Ratio: 36x
Alerts
Buy
91
TORXF alert for Apr 17
Torex Gold Resources [TORXF] is down 2.15% over the past day.
Sell
25
BULZ alert for Apr 17
MicroSectors Solactive FANG & Innov 3X Levd ETN [BULZ] is down 1.92% over the past day.
Sell
44
VIST alert for Apr 17
Vista Energy SAB de CV [VIST] is up 6.93% over the past day.
